Quarterly ResultAug 13, 2026, 04:04 PM
NuCana Q2 Net Loss £3.1M; Cash Runway to 2029; NUC-7738 Data on Track
AI Summary
NuCana plc announced its second quarter 2026 financial results and provided updates on its clinical development programs. The company reported a significantly reduced net loss of £3.1 million for Q2 2026, a substantial improvement from £24.1 million in Q2 2025. NuCana also extended its cash runway, with current cash and cash equivalents of £19.5 million expected to fund operations into 2029. Recruitment for the Phase 2 expansion study of NUC-7738 is complete, with final data anticipated later in 2026, and the company is engaging with the FDA regarding a potential registrational strategy for NUC-7738 in melanoma.
Key Highlights
- Cash and cash equivalents totaled £19.5 million as of June 30, 2026.
- Cash runway is expected to fund planned operations into 2029.
- Net loss for Q2 2026 significantly reduced to £3.1 million from £24.1 million in Q2 2025.
- Recruitment completed for NUC-7738 Phase 2 expansion study (NuTide:701).
- Final data from NUC-7738 Phase 2 study remains on track for release in 2026.
- Engaging with FDA to determine optimal path for NUC-7738 registrational strategy in melanoma.
- Advancing evaluation of additional indications and combination strategies for NUC-7738 and NUC-3373.
Price Impact
More from NCNA